« Back
Home /
Kanamycin (sulfate)

Kanamycin (sulfate)

Item no.	HY-16566A-200mg
Manufacturer	MedChem Express
CASRN	25389-94-0
Amount	200 mg
Quantity options	100 g 10 g 10 mM/1 mL 1 g 200 mg 25 g 50 g 5 g
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.96
Citations	[1]YANAGISAWA K, et al. Studies on kanamycin, a new antibiotic against tubercle bacilli. I. Effect on virulent tubercle bacilli in vitro and in mice. J Antibiot (Tokyo). 1957 Nov;10(6):233-5. \|[2]Nishi T, et al. Experimental respiratory tract infection with Klebsiella pneumoniae DT-S in mice: chemotherapy with kanamycin. Antimicrob Agents Chemother. 1980 Mar;17(3):494-505. \|[3]Misumi M, et al. Interaction of kanamycin and related antibiotics with the large subunit of ribosomes and the inhibition of translocation. Biochem Biophys Res Commun. 1978 Sep 29;84(2):358-65.\|[4]Misumi M, et al. Mechanism of inhibition of translocation by kanamycin and viomycin: a comparative study with fusidic acid. Biochem Biophys Res Commun. 1980 Jan 29;92(2):647-54. ACS Chem Biol. 2022 Jan 21;17(1):39-53. ACS Infect Dis. 2024 Apr 12;10(4):1327-1338. Cell Death Dis. 2021 May 18;12(6):509. Chin Med. 2025 Oct 3;20(1):155. Int J Hydrogen Energy. 2018, 43(30), 13821-13828. Microb Biotechnol. 2021 Nov;14(6):2538-2551. Nucleic Acids Res. 2022 Dec 9;50(22):12951-12968. Sci Adv. 2023 Feb 17;9(7):eade4770. ACS Infect Dis. 2025 Apr 11;11(4):929-939. Adv Sci (Weinh). 2024 Aug;11(31):e2308307. AMB Express. 2024 Dec 24;14(1):141. Aquat Toxicol. 2025 Feb 9:280:107284. bioRxiv. 2025 January 19. bioRxiv. 2025 May 29. BMC Microbiol. 2025 Apr 29;25(1):257. Commun Biol. 2025 Oct 6;8(1):1425. Food Chem. 2023 Mar 1:403:134399. Int Immunopharmacol. 2025 May 21:159:114888. Int J Med Microbiol. 2023 Mar 28;313(2):151578. iScience. 2025 Nov 12;28(12):114030. J Periodontol. 2024 Sep;95(9):867-879. Microbiol Spectr. 2025 Aug 29:e0059025. Microbiol Spectr. 2025 Oct 16:e0160325. mLife. 2025 Apr 15;4(2):155-168. Nat Microbiol. 2025 Nov;10(11):2949-2965. Vet Res Commun. 2024 Dec;48(6):3859-3872.
Smiles	OS(O)(=O)=O.O[C@H]1[C@](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@@]3([H])O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)([H])O[C@H](CN)[C@@H](O)[C@@H]1O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	Kanamycin A (sulfate)
Shipping Condition	Room temperature
Available
Manufacturer - Type	Natural Products
Manufacturer - Applications	COVID-19-immunoregulation
Manufacturer - Category	Reference compound / Active compounds; API; Natural Products
Manufacturer - Targets	Antibiotic; Bacterial
Manufacturer - HS Code	H360
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, sealed storage, away from moisture)
Molecular Weight	582.58
Product Description	Kanamycin (Kanamycin A) sulfate is an orally active antibacterial (gram-negative/positive bacteria) agent, inhibits translocation and causes misencoding by binding to the 70 S ribosomal subunit. Kanamycin sulfate shows good inhibitory activity to both M. tuberculosis (sensitive and drug-resistant ) and K. pneumonia, which can be used in studies of tuberculosis and pneumonia[1][2][3][4].
Manufacturer - Research Area	Infection
Solubility	DMSO : < 1 mg/mL\|H2O : ≥ 25 mg/mL
Manufacturer - Pathway	Anti-infection
Clinical information	Launched
UNSPSC Code	12352005
Precautionary	H360

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.